Revvity, Inc. at Wells Fargo Healthcare Conference Transcript
All right. Great. Welcome, everybody. Today, we have Prahlad Singh, CEO of Revvity. And maybe I'll just let you start.
I mean, you did announce a small tuck-in acquisition this morning. Maybe I'll let you kind of explain what you bought, how it fits in your portfolio and maybe what it let you do that you couldn't do prior.
Yeah. Good morning, Evan. Thank you for inviting us. I think as we've talked about, Human Cell Design is a great tuck-in acquisition for our reagents business, and it fits perfectly well with what we've talking about how our reagents business has been doing good on the preclinical stage.
As you go from preclinical to clinical, you go through looking at tissue culture, cell culture, cell lines and human cell designs that are as close to looking at humans possible. And going through this process, the Human Cell Design portfolio fits very well in our reagents business, and I think it will be a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
